Avisa Partners Acquires Top Intelligence Firm to Bring Comprehensive Global Investigations Offering to Clients
23.11.2022 19:28:00 EET | Business Wire | Press release
Avisa Partners today announced the acquisition and integration of Forward Risk and Intelligence LLC, a firm that conducts investigative due diligence, business intelligence research, and international risk assessments for investors, corporations, and law firms.
The announcement follows Avisa’s recent rapid expansion within the U.S. market, and the December 2021 acquisition of 35°Nord, an agency specializing in communications and influence strategies on the African continent.
The unique services provided by Forward Risk, based in Washington, D.C., complement and integrate seamlessly with Avisa’s existing advisory offerings, delivering a competitive edge for global corporations, private equity and hedge fund investors, law firms, international institutions, and high-net-worth individuals.
“Avisa Partners delivers elite advisory services to global clients working to solve complex and challenging matters,” said Eric Bovim, CEO of Avisa U.S. “With Forward Risk on board, Avisa can now expand its data-driven solutions to include investigative due diligence, strategic intelligence, and compliance.”
Forward Risk and Intelligence LLC will now be known as Forward Risk (An Avisa Partners Company) and retain its existing and independent website, branding, leadership team, and client roster. The firm’s 30 employees will integrate into Avisa’s U.S. headquarters in Washington, and its co-founders – Luke DiMaggio, Andrew Wooster, and Brendan Foo – will become partners of Avisa, with the ability to provide value-added services to all of Avisa Partners’ global clients.
“Joining Avisa Partners is a perfect fit given their scale and diverse advisory solutions that will yield immediate value for our clients,” said Forward Risk co-founder Brendan Foo. “Our best-in-class offering combined with Avisa’s global reach make this a win for all involved.”
About Forward Risk
Forward Risk (An Avisa Partners Company) is a corporate investigations, intelligence, and risk advisory firm headquartered in Washington, D.C. The firm’s experienced and resourceful team conducts investigative due diligence, business intelligence research, risk assessments, candidate vetting, and other bespoke intelligence services for asset managers, private equity, law firms, multinational corporations, and political campaigns. The firm emphasizes value-oriented results through thorough research, sophisticated analysis, clear writing, and thoughtful presentation.
About Avisa Partners
Avisa Partners is a global risk and reputation management firm that provides a comprehensive suite of advisory services to clients worldwide. Avisa’s 300 professionals, working in six cities across the globe, offer an established track-record of success working with blue-chip clients across industries, sectors, and geographies. The firm develops custom solutions to multi-stakeholder commercial, reputational, legal, regulatory, and public-perception challenges.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005581/en/
Contact information
Press contacts
Romain Grandjean
+33673475399
romain.grandjean@avisa-partners.com
Jean Tillinac
+33603939252
jean.tillinac@avisa-partners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Investment from Apollo —Achieves Unicorn Status27.4.2026 15:51:00 EEST | Press release
vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. Curodont™ supports enamel repair by facilitating the formation of crystalline mineral structure throughout the affected area, giving dental professionals an easy-to-use, restorative opti
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 15:30:00 EEST | Press release
Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to double down on connected TV, the need for greater visibility and performance insight has never been more important,” said Dana McGraw, SVP, Data and Measurement Science, Disney Advertising. “By collaborating with IAS, we’re helping provide advertisers with clearer
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-making. However, compared to Riskified’s agentic commerce pulse survey in Q4 2025, consumer sentiment has shifted, with growing concerns around fraud, security, and accountability slowing the path to fully autonomous, agent-driven transactions. Key findings from th
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 15:00:00 EEST | Press release
Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environment. The findings highlight a growing disconnect between ambition and execution. Cross-border transactions are expected to form a significant portion of deal pipelines, with 47% of respondents expecting them to account for between 26% and
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼ REZZAYO ® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 14:43:00 EEST | Press release
Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing allogeneic HSCT face prolonged periods of immunosuppression and routinely require extended antifungal prophylaxis,1 representing a setting where differentiated dosing, improved side effect profile, and reduced DDI is beneficial, and comparable efficacy is expected. The ReSPECT study met its primary endpoint for US Food and Drug Administration (FDA) and European Medicines
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom